Document Detail


Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia.
MedLine Citation:
PMID:  15711109     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Transurethral resection of the prostate is considered the standard technique for patients with moderate or severe lower urinary tract symptoms related to benign prostatic hyperplasia (BPH). Pathologically BPH is characterized by an increased proliferation of stromal and acinar cells, sustained by increased vascularization (neoangiogenesis). Recent studies have also shown that finasteride reduces angiogenesis and prostatic bleeding associated with BPH. Reducing the volume as a final step in reducing neoangiogenesis could thus represent a fundamental advance in limiting intra- and postoperative bleeding in patients undergoing transurethral resection of the prostate (TURP). MATERIALS AND METHODS: Our study included 60 patients undergoing TURP between January 2001 and January 2002. Of the patients, 30 received pretreatment with finasteride while 30 did not undergo any pretreatment (control group). In all the patients we evaluated the degree of peri-surgical bleeding, intended as a reduction in hemoglobin values in the 24 h following surgery. RESULTS AND CONCLUSIONS: In the group of patients pretreated with finasteride, blood loss, evaluated as a reduction in hemoglobin values, was minimal, and none of the patients required blood transfusion. The average hemoglobin loss in the 24 h following surgery was 0.9%. In the control group (average age 67 years), 4 patients (12%) required blood transfusion. The loss of hemoglobin was 2.36%. Finasteride, therefore, seems to play a fundamental role in the pretreatment of TURP patients, since by reducing dihydrotestosterone synthesis, it interacts with endothelial growth factors, thus reducing angiogenesis and preventing bleeding.
Authors:
G Crea; G Sanfilippo; G Anastasi; C Magno; C Vizzini; A Inferrera
Related Documents :
20094959 - Descending nerve-sparing radical prostatectomy--results and consequences.
7533689 - Benign prostatic hyperplasia: diagnosis and treatment options.
20639809 - Serenoa repens (permixon(r)) reduces intra- and postoperative complications of surgical...
11912399 - Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract...
20018319 - Prospective analysis of erectile dysfunction after anterior urethroplasty: incidence an...
8027619 - Pathogenesis of acute radiation injury to the rectum. a prospective study in patients.
24326799 - Oral misoprostol in the prevention of uterine bleeding after surgical evacuation of fir...
16148549 - Infliximab use in crohn's disease: impact on health care resources in the uk.
17344079 - Surgical treatment of capillary hemangiomas causing amblyopia.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Urologia internationalis     Volume:  74     ISSN:  0042-1138     ISO Abbreviation:  Urol. Int.     Publication Date:  2005  
Date Detail:
Created Date:  2005-02-15     Completed Date:  2005-05-17     Revised Date:  2006-10-30    
Medline Journal Info:
Nlm Unique ID:  0417373     Medline TA:  Urol Int     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  51-3     Citation Subset:  IM    
Affiliation:
Department of Urology, University Hospital of Messina, Messina, Italy. giov.crea@virgilio.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Blood Loss, Surgical / prevention & control*
Endoscopy* / adverse effects
Finasteride / therapeutic use*
Humans
Male
Preoperative Care
Prostatic Hyperplasia / surgery*
Chemical
Reg. No./Substance:
98319-26-7/Finasteride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Do BPH patients have neurogenic detrusor dysfunction? A uro-neurological assessment.
Next Document:  Subjective pain scale and the need for analgesia during shock wave lithotripsy.